{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:19:48Z","timestamp":1787840388886,"version":"build-2784847793"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"\n Purpose:<\/jats:title>\n To assess the safety and efficacy of the 4-year administration of 0.01% atropine following a 1-year observation period in high myopic children.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n The RAMCOM-II study continues the RAMCOM study, designed as an interventional nonrandomized study. Participants were observed for 1 year without any intervention to establish a baseline. Subsequently, children were divided into two arms: participants in the intervention group received one drop of 0.01% atropine daily at bedtime from years 1 to 5, while the control arm received no treatment and was monitored with routine clinical examinations. Annual assessments captured myopia progression, visual acuity, adverse events, and compliance. Statistical analyses compared outcomes between the two groups, considering demographic factors.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n At the 4-year follow-up, myopia progression from baseline in the intervention group (atropine-treated eyes) was significantly lower than in the control group (2.0 \u00b1 2.0 diopter [D] vs. 3.2 \u00b1 1.9 D,\n P<\/jats:italic>\n = 0.01). Axial elongation also favored the intervention group. At the 5-year follow-up, similar trends persisted, underscoring the sustained efficacy of 0.01% atropine. Myopia progression remained significantly reduced in the intervention group compared to the control group (2.2 \u00b1 2.0 D vs. 3.4 \u00b1 1.9 D,\n P<\/jats:italic>\n = 0.01). Although differences in axial elongation were less pronounced, these findings highlight the long-term benefits of 0.01% atropine in managing high myopia in children.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n The RAMCOM-II study supports the efficacy of 0.01% atropine in controlling myopia progression over 5 years, emphasizing its promising role in pediatric high myopia management.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/joco.joco_107_24","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T16:04:28Z","timestamp":1749139468000},"page":"291-295","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A Longitudinal Study Evaluating the Impact of 0.01% Atropine in High Myopic Children (RAMCOM-II Study)"],"prefix":"10.4103","volume":"36","author":[{"given":"Pradeep","family":"Agarwal","sequence":"first","affiliation":[{"name":"Department of Pediatric Ophthalmology, Strabismus and Neuro-Ophthalmology, CL Gupta Eye Institute, Moradabad, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veenu","family":"Maan","sequence":"additional","affiliation":[{"name":"Department of Pediatric Ophthalmology, Strabismus and Neuro-Ophthalmology, CL Gupta Eye Institute, Moradabad, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashi","family":"Khurana","sequence":"additional","affiliation":[{"name":"Department of Cornea and Anterior Segment, CL Gupta Eye Institute, Moradabad, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Sutar","sequence":"additional","affiliation":[{"name":"Department of Optometry and Visual Sciences, CL Gupta Eye Institute, Moradabad, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lokesh","family":"Chauhan","sequence":"additional","affiliation":[{"name":"Department of Clinical and Public Health Research, CL Gupta Eye Institute, Moradabad, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"R1-20250605","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050","volume":"123","author":"Holden","year":"2016","journal-title":"Ophthalmology"},{"key":"R2-20250605","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41433-018-0139-7","article-title":"Update in myopia and treatment strategy of atropine use in myopia control","volume":"33","author":"Wu","year":"2019","journal-title":"Eye (Lond)"},{"key":"R3-20250605","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/opo.12806","article-title":"Time trends on the prevalence of myopia in India \u2013 A prediction model for 2050","volume":"41","author":"Priscilla","year":"2021","journal-title":"Ophthalmic Physiol Opt"},{"key":"R4-20250605","doi-asserted-by":"crossref","first-page":"4395278","DOI":"10.1155\/2020\/4395278","article-title":"Recent epidemiology study data of myopia","volume":"2020","author":"Xiang","year":"2020","journal-title":"J Ophthalmol"},{"key":"R5-20250605","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaophthalmol.2023.2855","article-title":"Low-dose 0.01% atropine eye drops versus placebo for myopia control: A randomized clinical trial","volume":"141","author":"Repka","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"R6-20250605","doi-asserted-by":"crossref","first-page":"7113","DOI":"10.1038\/s41598-022-10079-1","article-title":"Efficacy of 0.01% low dose atropine and its correlation with various factors in myopia control in the Indian population","volume":"12","author":"Chaurasia","year":"2022","journal-title":"Sci Rep"},{"key":"R7-20250605","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.4103\/ijo.IJO_3157_20","article-title":"Efficacy of low-dose atropine to reduce myopia progression among Indian children","volume":"69","author":"Sivaraman","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"R8-20250605","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/APO.0000000000000256","article-title":"Low-concentration atropine eye drops for myopia progression","volume":"8","author":"Li","year":"2019","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"R9-20250605","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.4103\/ijo.IJO_679_22","article-title":"Role of 0.01% atropine in high myopic children of Moradabad, India (RAMCOM study)","volume":"70","author":"Agarwal","year":"2022","journal-title":"Indian J Ophthalmol"},{"key":"R10-20250605","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ophtha.2015.11.010","article-title":"Efficacy comparison of 16 interventions for myopia control in children: A network meta-analysis","volume":"123","author":"Huang","year":"2016","journal-title":"Ophthalmology"},{"key":"R11-20250605","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","article-title":"Five-year clinical trial on atropine for the treatment of myopia 2: Myopia control with atropine 0.01% eyedrops","volume":"123","author":"Chia","year":"2016","journal-title":"Ophthalmology"},{"key":"R12-20250605","first-page":"157","article-title":"Role of atropine in the control of myopia progression- a review","volume":"7","author":"Kaiti","year":"2022","journal-title":"Beyoglu Eye J"},{"key":"R13-20250605","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1186\/s12886-020-01746-w","article-title":"Efficacy and safety of atropine to control myopia progression: A systematic review and meta-analysis","volume":"20","author":"Zhao","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"R14-20250605","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.4103\/ijo.IJO_256_22","article-title":"Effect of atropine 0.01% on progression of myopia","volume":"70","author":"Sen","year":"2022","journal-title":"Indian J Ophthalmol"},{"key":"R15-20250605","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3390\/pharmaceutics14050900","article-title":"The role of atropine in preventing myopia progression: An update","volume":"14","author":"Chierigo","year":"2022","journal-title":"Pharmaceutics"},{"key":"R16-20250605","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.2174\/1381612821666150909095403","article-title":"The role of atropine eye drops in myopia control","volume":"21","author":"Grzybowski","year":"2015","journal-title":"Curr Pharm Des"}],"container-title":["Journal of Current Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/joco.joco_107_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:21:54Z","timestamp":1787836914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/joco.joco_107_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/joco.joco_107_24","relation":{},"ISSN":["2452-2325"],"issn-type":[{"value":"2452-2325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"2024-05-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}